Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatohepatitis.